JAK1 and Keratoconjunctivitis sicca: While these results are based on a rat corneal injury model and require confirmation in human studies, they suggest that JAK1, SKI, and ZBTB16 could represent candidate biomarkers for future diagnostic assays or targets for immunomodulatory therapy in dry eye [81].